Physician profile
James B Labus
NPI 1992732457
$1,645.50
in general payments reported to CMS, 2019-2025
18 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $235 · 2023: $330 · 2024: $394 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,254.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $287.20 | 2021-2025 | Belbuca |
| Boston Scientific Corporation | $251.42 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $195.80 | 2022-2024 | Accurian, Intellis Adaptivestim |
| Spr Therapeutics, INC | $192.20 | 2024 | Sprint Pns System |
| Averitas Pharma INC. | $166.45 | 2024-2025 | Qutenza |
| Vertex Pharmaceuticals Incorporated | $142.83 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.75 | 2025 | Relistor |
| Valinor Pharma, LLC | $49.82 | 2025 | Movantik |
| Forte Bio-Pharma LLC | $45.07 | 2021 | |
| Ibsa Pharma INC. | $42.04 | 2022-2023 | Tirosint, Licart |
| Pfizer INC. | $31.92 | 2021 | |
| Nevro Corp. | $27.91 | 2021-2024 | Senza |
| Merz Pharmaceuticals, LLC | $25.89 | 2023 | Xeomin |
| Protega Pharmaceutials INC | $22.60 | 2024 | Roxybond |
| Globus Medical, INC. | $20.72 | 2025 | Senza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.91 | 2025 | |
| Biodelivery Sciences International, INC. | $15.21 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $14.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Labus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.